gbt.com
Global Blood TherapeuticsVoxelotor for Sickle Cell Disease. About Sickle Cell Disease. GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease. GBT Announces New Employment Inducement Grants. Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock.
http://www.gbt.com/